

This article is reprinted on the Carter Center's website with permission from the American Society of Tropical Medicine and Hygiene.

Am. J. Trop. Med. Hyg., 89(4), 2013, pp. 717-720

Doi:10.4269/ajtmh.13-0299

Copyright © The American Society of Tropical Medicine and Hygiene

The Association between Latrine Use and Trachoma: A Secondary Cohort Analysis from a Randomized Clinical Trial

Meron Haile, Zerihun Tadesse, Sintayehu Gebreselassie, Berhan Ayele, Teshome Gebre, Sun N. Yu, Nicole E. Stoller, Bruce D. Gaynor, Travis C. Porco, Paul M. Emerson, Thomas M. Lietman and Jeremy D. Keenan*

Francis I. Proctor Foundation, University of California, San Francisco, California; The Carter Center, Addis Ababa, Ethiopia; Departments of Ophthalmology and Epidemiology and Biostatistics, University of California, San Francisco, California; The Carter Center, Atlanta, Georgia; Institute for Global Health, University of California, San Francisco, California

Abstract.

Latrine use has been promoted as a component of an integrated strategy for trachoma control. As part of a randomized trial in Ethiopia, 12 communities received a mass azithromycin distribution followed by a latrine promotion intervention. A random sample of children ages 0–9 years in each community was monitored longitudinally for ocular chlamydia. After latrine construction ended, those communities with a higher proportion of households using latrines were more likely to experience a reduction in the prevalence of ocular chlamydia. Specifically, for each 10% increase in latrine use, there was a 2.0% decrease (95% confidence interval = 0.2–3.9% decrease) in the community prevalence of ocular chlamydia over the subsequent year (

prompted us to perform a non–pre-specified secondary analysis to determine whether the prevalence of ocular chlamydia was related to the proportion of households using latrines.

METHODS

The study was conducted in the Amhara region of Ethiopia from May of 2006 to July of 2008;

coefficient. We performed similar analyses for the secondary outcome of change in TF/TI from month 12 to 24. We used Stata 10 (Statacorp, College Station, TX) for all analyses.

The study was approved by the University of California, San Francisco Committee on Human Research, the Ethiopian Science and Technology Commission, and Emory University. Informed consent in Amharic was obtained for all participants.

RESULTS

As reported previously, the median baseline prevalence of ocular chlamydia in children ages 0–9 years in 12 sentinel communities was 39.6% (interquartile range [IQR] = 31.9–57.1%).⁸ A mass azithromycin distribution of all community members was conducted several weeks later, with a median antibiotic coverage of 82.9% (IQR = 77.1–87.7%). Latrine promotion activities took place successfully in all 12 subkebeles over the subsequent year. At the 12-month study visit, the median prevalence of ocular chlamydia had decreased to 13.1% (IQR = 7.7–14.8%). At this time, the proportion of households with recent latrine use on inspection ranged from 20% (95% CI = 2.5–55.6%) to 90% (95% CI = 55.5–99.7%) (Figure 1). Over the next 12 months, the prevalence of ocular chlamydia infection increased by a median of 2.0% (IQR = 2.7% reduction to 6.6% increase).

Figure 1.

View larger version: [In this page](#) [In a new window](#)

Scatter plot of the proportion of households using a latrine versus the change in the prevalence of (A) ocular *Chlamydia* and (B) clinically active trachoma in 12 months after assessment of latrine use. Clinically active trachoma was defined as TF and/or TI according to the simplified WHO grading system. The dark grey line represents the regression line, and the light grey bars are the 95% CIs.

In univariate analyses, we found a correlation between the proportion of households with evidence of recent latrine use at 12 months and the change in prevalence of ocular chlamydia over the subsequent year (2.0% decrease [95% CI = 0.2–3.9% decrease] in the community prevalence of ocular chlamydia for each 10% increase in community latrine use, $P = 0.04$). The inclusion of several potential confounders did not change the magnitude of the association (Table 1). In contrast, we found no association between the proportion of households using a latrine and the change in the prevalence of TF/TI over the subsequent year (Figure 1 and Table 1).

Table 1

View this table: [In this window](#) [In a new window](#)

Multivariate sensitivity analyses assessing the influence of various confounders on the association between latrine use and trachoma

DISCUSSION

In this secondary analysis of a randomized clinical trial, we found that the higher the proportion

measured only a small number of potential confounding variables, which limited the multivariate analyses.

This study provides some evidence that the degree to which latrines are adopted by a community may be important for trachoma control, although this finding should be interpreted with caution given the negative clinical trial result using the same data. Additional research will be important to better characterize the role of the combined SAFE package for trachoma control.

Acknowledgments:

We thank the local health workers, community volunteers, and The Carter Center staff for conducting and coordinating field work. The authors thank the International Trachoma Initiative for their generous donation of azithromycin as well as the Amhara Regional Health Bureau and The Lions—Carter Center SightFirst Initiative for their support of the trachoma program in Ethiopia.

Footnotes:

Financial support: The main support for this study was National Institutes of Health Grants NEI U10 EY016214 and NEI K23 EY019071. Support was also provided by the International Trachoma Initiative (donation of azithromycin) as well as the Bernard Osher Foundation, That Man May See, the Bodri Foundation, the Harper Inglis Trust, the South Asia Research Fund, and Research to Prevent Blindness.

Received May 29, 2013.

Acceptsich to P ,02 r5 612 -792 reW Jw(uli)-2(on(1)-10m[(R)-0 12 72 6141.7651 Tm[(A)2(c)4(c)4(e)4(ps)6(i)-2r

5. Ngondi J, Matthews F, Reacher M, Baba S, Brayne C, Emerson P, 2008. Associations between active trachoma and community intervention with antibiotics, facial cleanliness, and environmental improvement (A, F, E). *PLoS Negl Trop Dis* 2: e229.
6. Ngondi J, Gebre T, Shargie EB, Adamu L, Ejigsemahu Y, Teferi T, Zerihun M, Ayele B, Cevallos V, King J, Emerson PM, 2009. Evaluation of three years of the SAFE strategy (surgery, antibiotics, facial cleanliness and environmental improvement) for trachoma control in five districts of Ethiopia hyperendemic for trachoma. *Trans R Soc Trop Med Hyg* 103: 1001–1010.
7. Astle WF, Wiafe B, Ingram AD, Mwangi M, Glassco CB, 2006. Trachoma control in Southern Zambia—an international team project employing the SAFE strategy. *Ophthalmic Epidemiol* 13: 227–236.
8. Stoller NE, Gebre T, Ayele B, Zerihun M, Assefa Y, Habte D, Zhou Z, Porco TC, Keenan JD, House JI, Gaynor BD, Lietman TM, Emerson PM, 2011. Efficacy of latrine promotion on emergence of infection with ocular *Chlamydia trachomatis* after mass antibiotic treatment: a cluster-randomized trial. *Int Health* 3: 75–84.
9. House JI, Ayele B, Porco TC, Zhou Z, Hong KC, Gebre T, Ray KJ, Keenan JD, Stoller NE, Whitcher JP, Gaynor BD, Emerson PM, Lietman TM, 2009. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. *Lancet* 373: 1111–1118.
10. Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, House JI, Yu SN, Ray KJ, Emerson PM, Keenan JD, Porco TC, Lietman TM, Gaynor BD, 2012. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. *Lancet* 379: 143–151.
11. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR, 1987. A simple system for the assessment of trachoma and its complications. *Bull World Health Organ* 65: 477–483.
12. Keenan JD, See CW, Moncada J, Ayele B, Gebre T, Stoller NE, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Schachter J, Lietman TM, 2012. Diagnostic characteristics of tests for ocular *Chlamydia* after mass azithromycin distributions. *Invest Ophthalmol Vis Sci* 53: 235–240.
13. Diamant J, Benis R, Schachter J, Moncada J, Pang F, Jha HC, Bhatta RC, Porco T, Lietman ests for

15. Ngondi J, Matthews F, Reacher M, Onsarigo A, Matende I, Baba S, Brayne C, Zingesser J, Emerson P, 2007. Prevalence of risk factors and severity of active trachoma in southern Sudan: an ordinal analysis. *Am J Trop Med Hyg* 77: 126–132.
16. Schémann J, Guinot C, Ilboudo L, Momo G, Ko B, Sanfo O, Ramde B, Ouedraogo A, Malvy D, 2003. Trachoma, flies and environmental factors in Burkina Faso. *Trans R Soc Trop Med Hyg* 97: 63–68.
17. Taylor HR, West SK, Mmbaga BB, Katala SJ, Turner V, Lynch M, Munoz B, Rapoza PA, 1989. Hygiene factors and increased risk of trachoma in central Tanzania. *Arch Ophthalmol* 107: 1821–1825.
18. Courtright P, Sheppard J, Lane S, Sadek A, Schachter J, Dawson CR, 1991. Latrine ownership as a protective factor in inflammatory trachoma in Egypt. *Br J Ophthalmol* 75: 322–325.
19. Burton MJ, Holland MJ, Makalo P, Aryee EA, Alexander ND, Sillah A, Faal H, West SK, Foster A, Johnson GJ, Mabey DC, Bailey RL, 2005. Re-emergence of *Chlamydia trachomatis* infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. *Lancet* 365: 1321–1328.
20. Rotondo LA, Ngondi J, Rodgers AF, King JD, Kamissoko Y, Amadou A, Jip N, Cromwell EA, Emerson PM, 2009. Evaluation of community intervention with pit latrines for trachoma control in Ghana, Mali, Niger and Nigeria. *Int Health* 1: 154–162.
21. Keenan JD, Lakew T, Alemayehu W, Melese M, House JI, Acharya NR, Porco TC, Gaynor BD, Lietman TM, 2011. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. *Arch Ophthalmol* 129: 512–513.
22. Simms VM, Makalo P, Bailey RL, Emerson PM, 2005. Sustainability and acceptability of latrine provision in The Gambia. *Trans R Soc Trop Med Hyg* 99: 631–637.